Ultragenyx sells priority review voucher for $210 million

· Health · United States

Ultragenyx Pharmaceutical is selling a priority review voucher to an undisclosed buyer for $210 million, one of the richest sales of the speedy-approval tool so far this year. The California company said it still holds another voucher it can monetize. Priority review vouchers are awarded by the FDA to sponsors of treatments for rare pediatric diseases and neglected tropical diseases, and can be transferred or sold to other companies seeking faster reviews for unrelated products. The price underscores continued demand for vouchers that shave months off the FDA review clock, even as buyers grow more selective. Ultragenyx's sale adds cash to its balance sheet as it advances its rare disease pipeline.

Why it matters：Priority review voucher prices are a barometer of how much companies will pay to accelerate approval timelines, and this sale signals the market for vouchers remains strong.

Key points

  • Ultragenyx is selling one priority review voucher for $210 million to an undisclosed buyer.
  • The company said it holds another voucher it can still monetize.
  • Priority review vouchers can be transferred or sold and shorten FDA review times.

Sources (original reporting)

More stories from this day